SPERO THERAPEUTICS INC's ticker is SPRO and the CUSIP is 84833T103. A total of 56 filers reported holding SPERO THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $0 | -100.0% | 204 | -94.8% | 0.00% | – |
| Q1 2022 | $35,000 | -96.3% | 3,930 | -93.3% | 0.00% | – |
| Q4 2021 | $940,000 | +413.7% | 58,742 | +489.5% | 0.00% | – |
| Q3 2021 | $183,000 | +137.7% | 9,965 | +79.1% | 0.00% | – |
| Q2 2021 | $77,000 | -75.9% | 5,564 | -74.3% | 0.00% | – |
| Q1 2021 | $319,000 | +145.4% | 21,640 | +223.0% | 0.00% | – |
| Q4 2020 | $130,000 | +35.4% | 6,700 | -21.7% | 0.00% | – |
| Q3 2020 | $96,000 | -26.2% | 8,558 | -11.9% | 0.00% | – |
| Q2 2020 | $130,000 | +282.4% | 9,709 | +124.7% | 0.00% | – |
| Q1 2020 | $34,000 | -68.8% | 4,320 | -62.0% | 0.00% | – |
| Q4 2019 | $109,000 | +87.9% | 11,361 | +106.3% | 0.00% | – |
| Q3 2019 | $58,000 | -25.6% | 5,508 | -18.9% | 0.00% | – |
| Q2 2019 | $78,000 | +136.4% | 6,789 | +164.5% | 0.00% | – |
| Q1 2019 | $33,000 | +1550.0% | 2,567 | +488.8% | 0.00% | – |
| Q4 2018 | $2,000 | -94.6% | 436 | -87.7% | 0.00% | – |
| Q3 2018 | $37,000 | +428.6% | 3,557 | +628.9% | 0.00% | – |
| Q2 2018 | $7,000 | -63.2% | 488 | -62.2% | 0.00% | – |
| Q1 2018 | $19,000 | +72.7% | 1,291 | +35.0% | 0.00% | – |
| Q4 2017 | $11,000 | – | 956 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Atlas Venture Associates IX, LLC | 1,376,968 | $17,639,000 | 16.57% |
| Aquilo Capital Management, LLC | 1,054,356 | $13,506,000 | 5.98% |
| VHCP Management II, LLC | 474,015 | $6,072,000 | 1.78% |
| AWM Investment Company, Inc. | 562,296 | $7,203,000 | 1.42% |
| Alphabet Inc. | 1,112,473 | $14,251,000 | 0.74% |
| BVF INC/IL | 460,706 | $5,902,000 | 0.66% |
| DAFNA Capital Management LLC | 70,000 | $897,000 | 0.39% |
| Artal Group S.A. | 600,000 | $7,686,000 | 0.31% |
| Rock Springs Capital Management LP | 525,000 | $6,725,000 | 0.26% |
| Orbimed Advisors | 507,471 | $6,501,000 | 0.10% |